Erasmus GBS Outcome Score (EGOS)
Erasmus GBS Outcome Score (EGOS): predicts the probability of being unable to walk independently 6 months after Guillain–Barré syndrome, from age, preceding diarrhoea and the GBS disability score 2 weeks after admission. Derived in patients unable to walk independently.
Score interpretation
Lower predicted risk of being unable to walk independently at 6 months (1 % at EGOS 1).
→ IVIG (adults: 0.4g/kg x 5 days) or plasmapheresis; physiotherapy; pain management; DVT prophylaxis; most patients walk at 6 months. Children: use a children's formulary.
Intermediate predicted risk of being unable to walk independently at 6 months.
→ IVIG or plasma exchange; ICU monitoring; respiratory function monitoring (FVC, NIF); may need ventilation; rehab planning; bladder care; nutritional support
High predicted risk of being unable to walk independently at 6 months (83 % at EGOS 7).
→ ICU admission; ventilatory support if FVC <20ml/kg or NIF <30cmH2O; autonomic monitoring (arrhythmia, BP swings); prolonged rehab; second IVIG if plateaued; tracheostomy if prolonged ventilation
Interpretation bands for the GBS EGOS Score. Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
- Gelatin (succinylated) · Colloid plasma volume expander
- Lanadelumab · Anti-plasma kallikrein monoclonal antibody
- Aciclovir 800mg Tablets (Ramsay Hunt Syndrome / Herpes Zoster Oticus) · Antiviral — nucleoside analogue (herpes zoster treatment)
- C1-esterase inhibitor · Plasma-derived complement inhibitor
- Berotralstat · Oral plasma kallikrein inhibitor
- Albumin solution · Plasma derivative / colloid
- Acute Stroke / TIA Assessment · NICE NG128; RCP Stroke Guidelines 2023
- Status Epilepticus (Adults) · NICE CG137; ESEM guidelines; RCP Neurology Guidelines
- Suspected Subarachnoid Haemorrhage · NICE NG228; RCEM 2023; AHA/ASA 2023
- Adult Head Injury · NICE NG232 (2023)
- Bell's Palsy / Facial Nerve Palsy · ENT UK 2017; AAN
- Vertigo Workup · ENT UK; NICE CKS
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.